A1CF | APOBEC1 complementation factor | | | | | | Tissue enhanced |
ABCG2 | ATP-binding cassette, sub-family G (WHITE), member 2 | Cancer-related genes CD markers Predicted membrane proteins
| | | | | Tissue enhanced |
ACTL7A | Actin-like 7A | Cytoskeleton related proteins
| | | | | Tissue enriched |
ADA | Adenosine deaminase | Disease related genes Enzymes FDA approved drug targets Plasma proteins
| | | | | Tissue enriched |
ADAM12 | ADAM metallopeptidase domain 12 | Enzymes Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enriched |
AFP | Alpha-fetoprotein | Cancer-related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
AGL | Amylo-alpha-1, 6-glucosidase, 4-alpha-glucanotransferase | Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Tissue enriched |
AHNAK2 | AHNAK nucleoprotein 2 | Cancer-related genes
| | | | | Tissue enriched |
AK4 | Adenylate kinase 4 | Enzymes Mitochondrial proteins Predicted secreted proteins
| | | | | Tissue enhanced |
AK5 | Adenylate kinase 5 | Enzymes
| | | | | Tissue enriched |
AKR1B1 | Aldo-keto reductase family 1, member B1 (aldose reductase) | Cancer-related genes Enzymes Plasma proteins
| | | | | Tissue enriched |
ALDH3A1 | Aldehyde dehydrogenase 3 family, member A1 | Enzymes
| | | | | Tissue enhanced |
ALDH6A1 | Aldehyde dehydrogenase 6 family, member A1 | Disease related genes Enzymes Mitochondrial proteins Potential drug targets Predicted membrane proteins
| | | | | Group enriched |
ALOX12 | Arachidonate 12-lipoxygenase | Disease related genes Enzymes Potential drug targets
| | | | | Group enriched |
ALX1 | ALX homeobox 1 | Disease related genes Transcription factors
| | | | | Tissue enhanced |
AMPH | Amphiphysin | Cancer-related genes
| | | | | Tissue enriched |
ANKRD2 | Ankyrin repeat domain 2 (stretch responsive muscle) | | | | | | Group enriched |
ANLN | Anillin, actin binding protein | | | | | | Tissue enhanced |
ANO1 | Anoctamin 1, calcium activated chloride channel | FDA approved drug targets Plasma proteins Predicted membrane proteins Transporters
| | | | | Tissue enhanced |
ANXA13 | Annexin A13 | Plasma proteins
| | | | | Tissue enhanced |
AOX1 | Aldehyde oxidase 1 | Enzymes Plasma proteins
| | | | | Tissue enhanced |
APOA4 | Apolipoprotein A-IV | Candidate cardiovascular disease genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
APOB | Apolipoprotein B | Candidate cardiovascular disease genes Disease related genes Plasma proteins Predicted secreted proteins
| | | | | Group enriched |
AQP4 | Aquaporin 4 | Predicted membrane proteins Transporters
| | | | | Group enriched |
ARG2 | Arginase 2 | Cancer-related genes Enzymes Mitochondrial proteins
| | | | | Group enriched |
ARHGAP28 | Rho GTPase activating protein 28 | | | | | | Tissue enhanced |
ASB9 | Ankyrin repeat and SOCS box containing 9 | | | | | | Tissue enhanced |
ASS1 | Argininosuccinate synthase 1 | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
ATP2B3 | ATPase, Ca++ transporting, plasma membrane 3 | Cancer-related genes Disease related genes Enzymes Plasma proteins Potential drug targets Predicted membrane proteins
| | | | | Group enriched |
AUNIP | Aurora kinase A and ninein interacting protein | | | | | | Tissue enhanced |
BAG2 | BCL2-associated athanogene 2 | Plasma proteins
| | | | | Tissue enhanced |
BARX2 | BARX homeobox 2 | Transcription factors
| | | | | Tissue enhanced |
BASP1 | Brain abundant, membrane attached signal protein 1 | Cytoskeleton related proteins Plasma proteins Transporters
| | | | | Tissue enhanced |
BCAN | Brevican | Plasma proteins Predicted secreted proteins
| | | | | Tissue enriched |
BCL2L14 | BCL2-like 14 (apoptosis facilitator) | | | | | | Tissue enhanced |
BHMT | Betaine--homocysteine S-methyltransferase | Enzymes Plasma proteins
| | | | | Group enriched |
BIN1 | Bridging integrator 1 | Disease related genes
| | | | | Tissue enriched |
BRIP1 | BRCA1 interacting protein C-terminal helicase 1 | Cancer-related genes Disease related genes Enzymes Potential drug targets
| | | | | Tissue enhanced |
BTK | Bruton agammaglobulinemia tyrosine kinase | Disease related genes Enzymes Plasma proteins Potential drug targets
| | | | | Tissue enhanced |
BTNL8 | Butyrophilin-like 8 | Predicted membrane proteins
| | | | | Group enriched |
C17orf53 | Chromosome 17 open reading frame 53 | | | | | | Tissue enhanced |
C1orf56 | Chromosome 1 open reading frame 56 | Predicted secreted proteins
| | | | | Tissue enriched |
C9orf117 | Chromosome 9 open reading frame 117 | | | | | | Tissue enriched |
CA4 | Carbonic anhydrase IV | Disease related genes Enzymes FDA approved drug targets Predicted membrane proteins Predicted secreted proteins
| | | | | Tissue enhanced |
CA9 | Carbonic anhydrase IX | Enzymes Predicted membrane proteins
| | | | | Tissue enhanced |
CABYR | Calcium binding tyrosine-(Y)-phosphorylation regulated | Cytoskeleton related proteins
| | | | | Tissue enriched |
CALB1 | Calbindin 1, 28kDa | | | | | | Tissue enriched |
CALB2 | Calbindin 2 | Plasma proteins
| | | | | Tissue enhanced |
CASC5 | Cancer susceptibility candidate 5 | Cancer-related genes Disease related genes Plasma proteins
| | | | | Tissue enhanced |
CAV1 | Caveolin 1, caveolae protein, 22kDa | Cancer-related genes Disease related genes Potential drug targets Predicted membrane proteins Transporters
| | | | | Tissue enhanced |